Talaris Therapeutics (TALS) director Mcdade received 348,949 shares
Insider transactions reported
Mark Mcdade (director at Talaris Therapeutics Inc., TALS) reported that they received 348,949 shares between Oct 19, 2023 and Oct 23, 2023. After these transactions the filing shows 348,431 shares held indirectly (By Qiming U.S. Healthcare Fund III,L.P.) and 518 shares held directly.
- Reporting person
- Mcdade Mark
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 19, 2023 | Grant or award (A) | Common Stock1, 2 | +348,431 | - | - | 348,431 indirect |
| Oct 19, 2023 | Grant or award (A) | Common Stock3 | +518 | - | - | 518 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 19, 2023 | Sale back to the company (D) | Stock Option (Right to Buy)On 20,500 Common Stock3, 7 | -20,500 | - | - | 0 direct |
| Oct 23, 2023 | Grant or award (A) | Stock Option (Right to Buy)On 20,000 Common Stock8 | +20,000 | - | - | 20,000 direct |
Holdings before and after
- Common Stock: 0 to 348,431 indirect, By Qiming U.S. Healthcare Fund III,L.P.
- Common Stock: 0 to 518 direct
- Stock Option (Right to Buy): 20,500 to 20,000 direct
Other positions listed
- Common Stock: 183,177 indirect, By Qiming U.S. Healthcare Fund I,L.P.
- Common Stock: 110,083 indirect, By Qiming U.S. Healthcare Fund II,L.P.
Footnotes from the filing
- 1. Received in exchange for 4,367,945 shares of common stock of Tourmaline Bio, Inc. ( Tourmaline ) pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the Merger Agreement ) by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ( Merger Sub ). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the Merger ), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc.
- 2. The securities are directly held by Qiming U.S. Healthcare Fund III, L.P. ( Qiming III ). Qiming U.S. Healthcare GP III, LLC ( Qiming GP III ) is the sole general partner of Qiming III. The Reporting Person is a managing member of Qiming GP III and may be deemed to share voting and dispositive power over the securities held by Qiming III. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- 3. Pursuant to the Merger Agreement, the Reporting Person's stock option to purchase 20,500 shares of Common Stock (prior to giving effect to the reverse stock split described in footnote (1)) was accelerated and cancelled at the effective time of the Merger. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to the reverse stock split).
- 4. Reflects a 10-for-1 reverse stock split of the Issuer's Common Stock effected on October 19, 2023 immediately prior to the effective time of the Merger.
- 5. The securities are directly held by Qiming U.S. Healthcare Fund I, L.P. ( Qiming ). Qiming U.S. Healthcare GP I, LLC ( Qiming GP ) is the sole general partner of Qiming. The Reporting Person is a managing member of Qiming GP and may be deemed to share voting and dispositive power over the securities held by Qiming. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- 6. The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ( Qiming II ). Qiming U.S. Healthcare GP II, LLC ( Qiming GP II ) is the sole general partner of Qiming II. The Reporting Person is a managing member of Qiming GP II and may be deemed to share voting and dispositive power over the securities held by Qiming II. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
- 7. The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.
- 8. The shares subject to the option vest in substantially equal monthly installments over a three-year period measured from one month following October 23, 2023, subject to the Reporting Person's continued service on each such vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Mcdade report in this TALS Form 4?
Mark Mcdade (director at Talaris Therapeutics Inc., TALS) reported that they received 348,949 shares between Oct 19, 2023 and Oct 23, 2023. After these transactions the filing shows 348,431 shares held indirectly (By Qiming U.S. Healthcare Fund III,L.P.) and 518 shares held directly.
How many TALS shares does Mcdade hold after this filing?
The filing shows 348,431 shares held indirectly (By Qiming U.S. Healthcare Fund III,L.P.), 518 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for TALS
Earlier insider filings at TALS
- Oct 24, 2023Kulkarni Sandeep Chidambar was granted 716,085 shares (SEC Form 4)
- Oct 24, 2023Kantoff Aaron was granted 37,891 shares (SEC Form 4)
- Oct 24, 2023Jones Susan Dana was granted 22,934 shares (SEC Form 4)
- Oct 24, 2023Johnson Kevin Bruce was granted 57,834 shares (SEC Form 4)
- Oct 24, 2023Chyung Yung H. was granted 56,836 shares (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow TALS and get a push notification the moment its next story breaks.